A double blind crossover trial of lithium carbonate in asthma.
Lithium carbonate was evaluated in a double-blind, crossover study for prophylactic therapy in five patients with severe perennial asthma. There were no significant differences in symptom scores, salbutamol inhalations, PEFR and pulmonary function tests when the baseline, placebo and lithium periods were compared in all patients.